Cargando…

Performance of p16(INK4a) ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study

OBJECTIVE: A biomarker with increased specificity for cervical dysplasia compared with human papillomavirus (HPV) testing would be an attractive option for cervical cancer screening among HIV-infected women in resource-limited settings. p16(INK4a) has been explored as a biomarker for screening in ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Tara J, Smith-McCune, Karen, Reuschenbach, Miriam, von Knebel Doeberitz, Magnus, Maloba, May, Huchko, Megan J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030582/
https://www.ncbi.nlm.nih.gov/pubmed/27625065
http://dx.doi.org/10.1136/bmjopen-2016-012547
_version_ 1782454703937814528
author Wu, Tara J
Smith-McCune, Karen
Reuschenbach, Miriam
von Knebel Doeberitz, Magnus
Maloba, May
Huchko, Megan J
author_facet Wu, Tara J
Smith-McCune, Karen
Reuschenbach, Miriam
von Knebel Doeberitz, Magnus
Maloba, May
Huchko, Megan J
author_sort Wu, Tara J
collection PubMed
description OBJECTIVE: A biomarker with increased specificity for cervical dysplasia compared with human papillomavirus (HPV) testing would be an attractive option for cervical cancer screening among HIV-infected women in resource-limited settings. p16(INK4a) has been explored as a biomarker for screening in general populations. DESIGN: A 2-year cross-sectional study. SETTING: 2 large HIV primary care clinics in western Kenya. PARTICIPANTS: 1054 HIV-infected women in western Kenya undergoing cervical cancer screening as part of routine HIV care from October 2010 to November 2012. INTERVENTIONS: Participants underwent p16(INK4a) specimen collection and colposcopy. Lesions with unsatisfactory colposcopy or suspicious for cervical intraepithelial neoplasia 2+ (CIN2+; including CIN2/3 or invasive cervical cancer) were biopsied. Following biopsy, disease status was determined by histopathological diagnosis. PRIMARY AND SECONDARY OUTCOME MEASURES: We measured the sensitivity, specificity and predictive values of p16(INK4a) ELISA for CIN2+ detection among HIV-infected women and compared them to the test characteristics of current screening methods used in general as well as HIV-infected populations. RESULTS: Average p16(INK4a) concentration in cervical samples was 37.4 U/mL. After colposcopically directed biopsy, 127 (12%) women were determined to have CIN2+. Receiver operating characteristic analysis showed an area under the curve of 0.664 for p16(INK4a) to detect biopsy-proven CIN2+. At a p16(INK4a) cut-off level of 9 U/mL, sensitivity, specificity, positive and negative predictive values were 89.0%, 22.9%, 13.6% and 93.8%, respectively. The overall p16(INK4a) positivity at a cut-off level of 9 U/mL was 828 (78.6%) women. There were 325 (30.8%) cases of correct p16(INK4a) prediction to detect or rule out CIN2+, and 729 (69.2%) cases of incorrect p16(INK4a) prediction. CONCLUSIONS: p16(INK4a) ELISA did not perform well as a screening test for CIN2+ detection among HIV-infected women due to low specificity. Our study contributes to the ongoing search for a more specific alternative to HPV testing for CIN2+ detection.
format Online
Article
Text
id pubmed-5030582
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-50305822016-10-04 Performance of p16(INK4a) ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study Wu, Tara J Smith-McCune, Karen Reuschenbach, Miriam von Knebel Doeberitz, Magnus Maloba, May Huchko, Megan J BMJ Open Obstetrics and Gynaecology OBJECTIVE: A biomarker with increased specificity for cervical dysplasia compared with human papillomavirus (HPV) testing would be an attractive option for cervical cancer screening among HIV-infected women in resource-limited settings. p16(INK4a) has been explored as a biomarker for screening in general populations. DESIGN: A 2-year cross-sectional study. SETTING: 2 large HIV primary care clinics in western Kenya. PARTICIPANTS: 1054 HIV-infected women in western Kenya undergoing cervical cancer screening as part of routine HIV care from October 2010 to November 2012. INTERVENTIONS: Participants underwent p16(INK4a) specimen collection and colposcopy. Lesions with unsatisfactory colposcopy or suspicious for cervical intraepithelial neoplasia 2+ (CIN2+; including CIN2/3 or invasive cervical cancer) were biopsied. Following biopsy, disease status was determined by histopathological diagnosis. PRIMARY AND SECONDARY OUTCOME MEASURES: We measured the sensitivity, specificity and predictive values of p16(INK4a) ELISA for CIN2+ detection among HIV-infected women and compared them to the test characteristics of current screening methods used in general as well as HIV-infected populations. RESULTS: Average p16(INK4a) concentration in cervical samples was 37.4 U/mL. After colposcopically directed biopsy, 127 (12%) women were determined to have CIN2+. Receiver operating characteristic analysis showed an area under the curve of 0.664 for p16(INK4a) to detect biopsy-proven CIN2+. At a p16(INK4a) cut-off level of 9 U/mL, sensitivity, specificity, positive and negative predictive values were 89.0%, 22.9%, 13.6% and 93.8%, respectively. The overall p16(INK4a) positivity at a cut-off level of 9 U/mL was 828 (78.6%) women. There were 325 (30.8%) cases of correct p16(INK4a) prediction to detect or rule out CIN2+, and 729 (69.2%) cases of incorrect p16(INK4a) prediction. CONCLUSIONS: p16(INK4a) ELISA did not perform well as a screening test for CIN2+ detection among HIV-infected women due to low specificity. Our study contributes to the ongoing search for a more specific alternative to HPV testing for CIN2+ detection. BMJ Publishing Group 2016-09-13 /pmc/articles/PMC5030582/ /pubmed/27625065 http://dx.doi.org/10.1136/bmjopen-2016-012547 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Obstetrics and Gynaecology
Wu, Tara J
Smith-McCune, Karen
Reuschenbach, Miriam
von Knebel Doeberitz, Magnus
Maloba, May
Huchko, Megan J
Performance of p16(INK4a) ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study
title Performance of p16(INK4a) ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study
title_full Performance of p16(INK4a) ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study
title_fullStr Performance of p16(INK4a) ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study
title_full_unstemmed Performance of p16(INK4a) ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study
title_short Performance of p16(INK4a) ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study
title_sort performance of p16(ink4a) elisa as a primary cervical cancer screening test among a large cohort of hiv-infected women in western kenya: a 2-year cross-sectional study
topic Obstetrics and Gynaecology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030582/
https://www.ncbi.nlm.nih.gov/pubmed/27625065
http://dx.doi.org/10.1136/bmjopen-2016-012547
work_keys_str_mv AT wutaraj performanceofp16ink4aelisaasaprimarycervicalcancerscreeningtestamongalargecohortofhivinfectedwomeninwesternkenyaa2yearcrosssectionalstudy
AT smithmccunekaren performanceofp16ink4aelisaasaprimarycervicalcancerscreeningtestamongalargecohortofhivinfectedwomeninwesternkenyaa2yearcrosssectionalstudy
AT reuschenbachmiriam performanceofp16ink4aelisaasaprimarycervicalcancerscreeningtestamongalargecohortofhivinfectedwomeninwesternkenyaa2yearcrosssectionalstudy
AT vonknebeldoeberitzmagnus performanceofp16ink4aelisaasaprimarycervicalcancerscreeningtestamongalargecohortofhivinfectedwomeninwesternkenyaa2yearcrosssectionalstudy
AT malobamay performanceofp16ink4aelisaasaprimarycervicalcancerscreeningtestamongalargecohortofhivinfectedwomeninwesternkenyaa2yearcrosssectionalstudy
AT huchkomeganj performanceofp16ink4aelisaasaprimarycervicalcancerscreeningtestamongalargecohortofhivinfectedwomeninwesternkenyaa2yearcrosssectionalstudy